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Previously, we generated a murine monoclonal antibody (mAb), KR127, that recognizes amino acids (aa) 37–45 of the preS1 of hepatitis
B virus (HBV). In this study, we have constructed a humanized version of KR127 and evaluated its HBV-neutralizing activity in
chimpanzees. A study chimpanzee was given a single intravenous dose of the humanized antibody, followed by intravenous challenge with
adr subtype of wild type HBV, while a control chimpanzee was only challenged with the virus. The result showed that the study chimpanzee
did not develop HBV infection during 1 year, while the control chimpanzee was infected, indicating that the humanized antibody exhibited in
vivo virus-neutralizing activity and thus protected the chimpanzee from HBV infection. In addition, the humanized antibody bound to the
preS1 of all subtypes of HBV. We first demonstrate that an anti-preS1 mAb can neutralize HBV infection in vivo. This humanized antibody
will be useful for the immunoprophylaxis of HBV infection.
D 2003 Elsevier Inc. All rights reserved.Keywords: Hepatitis B virus; preS1; Humanized antibody; Neutralization; ChimpanzeeIntroduction
Hepatitis B virus (HBV) infection is a worldwide public
health problem affecting 300 million persistent chronic
carriers having a high risk to develop hepatocellular carci-
noma (Tiollais and Buendia, 1991). For the prevention or
post-exposure prophylaxis of HBV infection, hepatitis B
immune globulin (HBIG) prepared from pooled human anti-
HBsAg plasma is administered to infants born of HBsAg–
HBeAg positive mothers at birth, susceptible individuals
with an acute exposure to infectious HBV-containing mate-
rial or orthotopic liver transplant patients with chronic HBV-
related liver disease (Beasley et al., 1983; McGory et al.,
1996; Sawyer et al., 1998; Terrault et al., 1996). However,
the currently available HBIG is not an ideal source of
antibody due to the limited availability and low specific
activity. Therefore, monoclonal antibodies (mAbs) specific0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: hjhong@kribb.re.kr (H.J. Hong).to the surface antigens of HBV would be a good alternative
for the immunoprophylaxis of HBV infection.
The HBV envelope contains three related surface glyco-
proteins called the large (L), middle (M), and small (S)
proteins. All these proteins are the product of a single open
reading frame that is divided into the preS1, preS2, and S
regions (Heermann et al., 1984). The S protein is encoded
by the S region. The M protein contains the preS2 and S
regions, and the L protein contains the preS1, preS2, and S
regions. The S protein carries the common a determinant
and two sets of mutually exclusive subtype determinants d/y
and w/r, and thus the four major subtypes (adw, adr, ayw,
and ayr) of the HBsAg denote the antigenic types of HBV
(Courouce et al., 1982). In addition to the infectious virus
particles, cells infected by HBV produce large quantities of
noninfectious subviral particles of two other morphological
forms, 22-nm spherical particles and filaments of 22-nm
diameter. The S and M proteins are found on all three
particle types, whereas the L protein is preferentially local-
ized on infectious viral particles (Heermann et al., 1984;
Stibbe and Gerlich, 1983). The preS1 of the L protein has
been shown to have a pivotal function in viral infectivity
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Ou and Rutter, 1987; Persing et al., 1986; Pontisso et al.,
1989; Ryu et al., 2000a, 2000b). Especially, the amino acids
(aa) 21–47 of the preS1 have been proposed to contain a
specific binding site for human hepatocyte receptor (De
Falco et al., 2001; Neurath et al., 1986; Pontisso et al.,
1989). Therefore, anti-preS1 mAb that is capable of block-
ing the cell attachment by HBV will be advantageous for the
immunoprophylaxis of HBV infection.
Regarding the immune defense mechanisms, the aa 12–
47 of the preS1, the aa 1–26 of the preS2, and the common
a determinant of the S protein were shown to elicit virus-
neutralizing and protective antibodies (Bhatnager et al.,
1982; Dreesman et al., 1982; Heermann et al., 1987; Itoh
et al., 1986; Klinkert et al., 1986; Milich, 1987; Neurath et
al., 1989). In addition, a single mAb specific to the common
a determinant of the S protein was demonstrated to have
virus-neutralizing activity in chimpanzees or humans (Eren
et al., 2000; Galun et al., 2002; Heijtink et al., 1999; Ogata
et al., 1993). However, in vivo virus-neutralizing activity of
anti-preS1 mAb has not been demonstrated.
Murine mAbs are easy to produce, but their therapeutic
use in humans is limited because of human anti-mouse
antibody response during treatment (Shawler et al., 1985).
One valuable solution is to humanize murine mAbs. Hu-
manized antibodies have been constructed by grafting the
mouse complementarity determining regions (CDRs), which
form antigen-binding pocket, onto homologous human
antibody variable regions, while retaining some murine
residues in framework regions (FRs) that are predicted to
influence the conformation of CDRs (Queen et al., 1989;
Riechmann et al., 1988). Several humanized antibodies are
in clinical use in humans (Reichert, 2001).
Previously, we generated a murine mAb, KR127, that
recognizes the aa 37–45 of the preS1 (Ryu et al., 2000a,
2000b). The antibody showed neutralizing activity against
both the adr and ayw subtypes of the virus in an in vitro
infection of adult human hepatocyte primary culture by
HBV (Maeng et al., 2000). In this study, we have con-
structed the humanized version of KR127 and evaluated its
in vivo HBV-neutralizing activity in chimpanzees. The
result showed that a single dose of the humanized antibody
protected the chimpanzee from HBV infection. In addition,
the humanized antibody bound to the preS1 of all subtypes
of HBV. This anti-preS1 mAb will be potentially useful in
the immunoprophylaxis of HBV infection.Results and discussion
Cloning and sequence analysis of the VH and VL of KR127
To construct the humanized version (HzKR127) of
KR127, the cDNAs encoding the heavy (VH) or light
(VL) chain variable region of KR127 were cloned from
hybridoma KR127, as described in Materials and methods,and their nucleotide sequences were determined. The se-
quence analysis indicated that the VH belongs to mouse
heavy chain subgroup II(A), while the VL belongs to mouse
n chain subgroup II (Kabat et al., 1991). The CDR1, CDR2,
and CDR3 of the VH and VL are indicated (Fig. 1). The
KR127 VH was the most homologous to human germ line
DP7 and JH4, with 74% identity in the FR, while the
KR127 VL was the most homologous to DPK12 and JK4,
with 85% identity in the FR (Fig. 1).
Construction and affinity determination of humanized
KR127
For the construction of the humanized VH, the CDR1,
partial CDR2 (aa 50–58), CDR3, and 11 FR residues of
KR127 VH were grafted onto the composite of human DP7
and JH4 (Fig. 1A). For the construction of the humanized
VL, the CDRs and five FR residues of KR127 VL were
grafted onto the composite of human DPK12 and JK4 (Fig.
1B). The resulting humanized VH and VL were individually
combined with human g1 and n constant regions, respec-
tively, and then fused to the HCMV promoter to construct
the heavy chain expression plasmid, pCMV-HKR127(I) and
the light chain expression plasmid, pKC-dhfr-HKR127,
respectively.
For the production of the humanized antibody, the
expression plasmids were introduced into the dihydrofolate
reductase (DHFR)-deficient Chinese hamster ovary (CHO)
cell line, and several recombinant CHO cell lines that stably
produced the humanized antibody were selected and sub-
jected to successive rounds of methotrexate (MTX) selec-
tion. Finally, a high producer cell line was grown in serum-
free medium and the culture supernatant was subjected to
affinity purification of the humanized antibody.
The antigen-binding affinity of the humanized antibody
was determined by competition ELISA. The affinity (1 
108 M1) of the humanized antibody (HzKR127) for the
preS1 antigen was similar to that of KR127 (Fig. 2).
In vivo virus-neutralizing activity of humanized KR127 in
chimpanzees
The study chimpanzee (CA0231) was given an intrave-
nous injection of the humanized antibody (5 mg/kg) and 3
days later, the animal was challenged with 105 dilution of
human sera containing wild type HBV (adr subtype), whose
end-point infectivity titer in chimpanzees had been deter-
mined to be 108 (Tabor et al., 1983), while the control
chimpanzee (CA0218) was only challenged with the same
dose of the virus. The course of HBV infection in the
chimpanzees was monitored by serological and biochemical
analyses of the sera for 1 year. In the case of the control
chimpanzee (Fig. 3A), serum HBsAg became positive from
the 14th to 20th week and elevated serum levels of liver
enzymes (alanine aminotransferase and aspartate aminotrans-
ferase) were detected from 20th to 21st week. Also, actively
Fig. 1. Nucleotide sequence and derived amino acid sequence of the VH (A) and VL (B) of murine and humanized KR127 antibody. Amino acid numbers and
CDRs are assigned according to Kabat et al. (1991). The CDR1, CDR2, and CDR3 of the VH and VL are underlined. Dashes indicate identical amino acid
residues.
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from the 19th and 23rd week, respectively, and remained at
elevated level through the end-point of this experiment.
In contrast, in the case of the study chimpanzee, neither
HBsAg nor actively acquired anti-HBV antibody was
detected during 1 year, while the administered humanized
antibody was detected for 14 weeks (Fig. 3B). The results
indicate that the humanized antibody neutralized the virus in
vivo and thus protected the chimpanzee from HBV infec-
tion. The humanized antibody had a half-life of approxi-
mately 10 days in the challenged chimpanzee, which is
faster compared to that of human IgG in an unchallenged
chimpanzee or human. This may be because the humanized
antibody molecules bound to the challenged HBV were
eliminated from the blood of the challenged chimpanzee.Binding ability of humanized KR127 for different subtypes
of HBV
We could not test the in vivo virus-neutralizing activity of
humanized KR127 against the other subtypes of HBV
because the animal study using chimpanzees was expensive.
To explore the binding ability of the humanized antibody for
different subtypes of HBV, to begin with, the amino acid
sequences of aa 20–50 of all the preS1 listed in the GenBank
databases were aligned and compared (Fig. 4). The sequence
comparison revealed that amino acid substitutions occurred
at position 38 (from serine to threonine) and position 39
(from asparagine to histidine, threonine, or alanine), whereas
the other positions in the epitope are conserved among all the
subtypes of HBV. To investigate the role of the positions 38
Fig. 2. Affinity determination of murine and humanized KR127 antibody
by a competitive ELISA. A solution containing 3 ng of the purified
antibody and various concentrations (1011–106 M) of the GST-preS1
protein as a competing antigen was preincubated at 37 jC for 3 h and added
to each well that was coated with 0.1 Ag of the GST-preS1, then an indirect
ELISAwas done. Apparent affinity was determined as the reciprocal of the
antigen concentration required to inhibit 50% maximal binding in the
competitive ELISA.
Fig. 3. The course of HBV infection showing the appearance of HBsAg and anti-
level of the humanized KR127 in the study chimpanzee (B).
Fig. 4. Sequence alignment of aa 20–50 of various subtypes and variants of
HBV preS1. Query is the preS1 sequence (adr subtype) used in this study.
The sequences starting with number 20 are ad subtype, while those with
number 9 are ay subtype because the first 11 amino acids of ad subtype are
missing in ay subtype. A hyphen indicates an amino acid residue identical
to that of the query sequence. The epitope of KR127 is indicated on the top
of the sequence. The sequences whose subtypes are identified in the
GenBank databases are noted. The number of identical sequences among
total 48 preS1 sequences listed in the GenBank databases is written in the
parentheses after amino acid sequences.
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the epitope was performed and the alanine substitution
mutants of the preS1 were subjected to Western blot analysis
using humanized KR127 (Figs. 5A and 5B). The result
showed that alanine substitution at Ser38 (S38A) or Asn39HBV antibodies in the serum of the control chimpanzee (A) and the serum
Fig. 5. Binding ability of humanized KR127 to the alanine substitution
mutants of the epitope (A, B) or the preS1 of different subtypes of HBV (C,
D). Each residue in the epitope (aa 37–45) was substituted by alanine and a
series of the alanine substitution mutants of the preS1(aa 1–56) was
expressed in Escherichia coli as GST fusion proteins. The GST-preS1
fusion proteins were purified and subjected to 12.5% SDS-PAGE (A) and
Western blot analysis using humanized KR127 (B). GST fusion proteins
with preS1(1–56) of wild type, N39H, N39T, or S38T/N39A mutants were
subjected to 12.5% SDS-PAGE (C) and Western blot analysis using
humanized KR127 (D). Approximately 2 Ag of the protein was run in each
lane.
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the other positions completely abrogated the antibody bind-
ing. The data indicate that the positions 38 and 39, showing a
little sequence variation, may not be directly involved in
antibody binding, while the other residues, conserved among
all subtypes of HBV, are critical for antibody binding. This
suggests that the humanized antibody is capable of binding
to all subtypes of HBV.
To confirm the binding ability of the humanized antibody
for different subtypes of HBV, three preS1 variants carrying
N39H (I01492), N39T (P03142), or S38T/N39A (A32622),
which represent all the subtypes and variants listed in the
databases, were constructed, expressed, and subjected to
Western blot analysis using humanized KR127. The result
showed that the humanized antibody bound to all the preS1
variants (Figs. 5C and 5D), suggesting that it could bind to
and neutralize all the subtypes of HBV, like anti-S mAb
specific to the common a determinant.
For the prevention or post-exposure prophylaxis of HBV
infection, human mAbs specific to the common a determi-
nant of the S protein have been developed and their
protective or therapeutic activities have been demonstrated
in chimpanzees or humans (Eren et al., 2000; Galun et al.,
2002; Heijtink et al., 1999; Ogata et al., 1993). In this study,
we first demonstrate that anti-preS1 mAb is capable of
neutralizing HBV infection in vivo. In addition, the human-
ized antibody bound to all subtypes of HBV. Therefore, the
humanized KR127 will be useful for the immunoprophy-
laxis of HBV infection. Especially, considering that thesubviral particles are usually present in a 10,000- to
1,000,000-fold excess over complete viral particles in the
blood of infected persons and the preS1 antigen is prefer-
entially localized on the infectious viral particles, anti-preS1
antibody would selectively bind to infectious viral particles
among large quantities of subviral particles and reduce the
titer of infectious viral particles more efficiently than anti-S
antibody, if their antigen-binding affinities are equal. The
humanized antibody will be also useful for the immunopro-
phylaxis of the escape mutants of the common a determinant
(Fujii et al., 1992; Kohno et al., 1996; McMahon et al.,
1992; Terrault et al., 1998). Recently, we successfully
constructed a more advanced humanized KR127 version
that has much less mouse residues and higher affinity
compared to the humanized antibody used in this study
(data not shown). We expect that the improved humanized
antibody may be useful in the prevention and therapy of
HBV infection and hepatitis.Materials and methods
Cell culture
Murine hybridoma were cultured routinely at 5% CO2, 37
jC in IMDM (GIBCO/BRL) supplemented with 10% (v/v)
fetal bovine serum (GIBCO/BRL). The DHFR-deficient
CHO cell line, DG44, was used for stable expression of the
humanized antibody. The DG44 cells were grown at 5%CO2,
37 jC in DMEM/F12 (GIBCO/BRL) supplemented with
hypoxanthine (10 mg/l), thymidine (10 mg/l), glycine (50
mg/l), glutamine (587 mg/l), glucose (4.5 mg/l), 10% fetal
bovine serum, and antibiotics–antimycotics (GIBCO/BRL).
Construction of humanized KR127
Cloning of the cDNAs encoding the variable region of
KR127
Total RNA was isolated from KR127 hybridoma (Ryu et
al., 2000a, 2000b), and the cDNAs encoding the variable
regions of KR127 were synthesized by polymerase chain
reaction (PCR) using the 5V- and 3V-primers specific for the
heavy or light chain of murine antibodies (Ryu et al., 1994).
After the cDNA synthesis, the PCR products were subcl-
oned into pBluescript SK(+). The three clones of the VH or
VL cDNA were sequenced by dideoxy chain termination
method using Sequenase (USB, USA). The VH or VL
cDNA clones had identical nucleotide sequences and were
named pKR127H or pKR127K, respectively.
Construction of humanized KR127 heavy chain
Comparison of the amino acid sequences between the
heavy and light chain variable regions of KR127 and human
immunoglobulin germ line segments showed that DP7 and
DPK12 were the most homologous to the VH and VL of
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chain variable region gene, 11 FR residues and 3 CDR2
residues of KR127 VH were replaced with those of human
DP7. The amino acid sequences of the mouse, human and
humanized VH are shown in Fig. 1A. The humanized VH
was synthesized by recombinant PCR using pKR127H as a
template and eight synthetic oligonucleotides as PCR pri-
mers. The nucleotide sequences of the PCR primers are the
following: #1: 5V-GAG AAT TCA CAT TCA CGA TGT
ACT TG-3V; #2: 5V-GGC CCC AGG CTT CAC CAC TTC
AGC TCC-3V; #3: 5V-GTG AAG CCT GGG GCC TCA-3V;
#4: 5V-AGA ACTACT GAATGCGTAGCC AGAAGC-3V;
#5: 5V-GCATTC AGTAGT TCT TGG ATG AAC TGG-3V;
#6: 5V-AAT CCG TCC AAT CCA CTC AAG ACC CTG-3V;
#7: 5V-TGG ATT GGA CGG ATT TAT CCT-3V; #8: 5V-GGA
TTT GTC TGC AGT CAG TGT GGC CTT GCC CTG
GAA CTT-3V; #9: 5V-ACT GCA GACAAATCC ACG AGC
ACA GCC TAC ATG GAG CTC-3V; #10: 5V-GTC GTA
CTC TCT TGC ACA GAA ATA GAC CGC CGT-3V; #11:
5V-GCA AGA GAG TAC GAC GAG GCT TAC TGG GGC
CAA-3V; #12: 5V-CGG TCG ACT CAT TTA CCC GGA
GAC AG-3V. The primers 1 and 12 contain EcoRI and SalI
sites, respectively. The humanized VH sequence was fused
to human g1 constant region sequence in pCHC-S2 (Ryu et
al., 1996) by recombinant PCR, and the final PCR product
was digested with EcoRI and SalI and subcloned into pBlue-
script SK(+) to yield pHKR127HC. Subsequently, to con-
struct the humanized heavy chain expression plasmid, the
pHKR127HC DNA was digested with SalI and NotI, and
subcloned into the SalI–NotI sites of pRc/CMV (Invitrogen)
to yield pCMV-HKR127HC.
Construction of humanized KR127 light chain
Seven murine FR residues were replaced with those of
human DPK12. The amino acid sequences of the mouse,
human, and humanized VL are shown in Fig. 1B. The
humanized VL was synthesized by recombinant PCR using
pKR127K as a template and six synthetic oligonucleotides
as primers. The nucleotide sequences of the PCR primers
are the following: #13: 5V-CAA AGC TG GAA GCA AGA
TGG ATT CA-3V; #14: 5V-TGG AGT TTG GGT CAT CAA
GAT ATC CCC ACA GGT ACC-3V; #15: 5V-ATG ACC
CAA ACT CCA CTT TCT TTG TCG GTT ACC CCT
GGA CAA CCA GCC-3V; #16: 5V-CAC CAG ATA GAT
TAG GCG CTT TGG AGA CTG GCC TGG CTT-3V; #17:
5V-CTA ATC TAT CTG GTG TCT AAA CTG GAC TCT
GGA GTC CCT-3V; #18: 5V-GAA GTC GAC CTA ACA
CT-3V. The primer 13 and 18 contain HindIII and SalI sites,
respectively. The humanized VL was fused to the human n
constant region sequence in pCKC-S2 (Ryu et al., 1996) by
recombinant PCR. The final PCR product was digested
with HindIII and SalI and subcloned into pBluescript
SK(+) to yield pHKR127KC. To construct the humanized
light chain expression plasmid, the pHKR127KC was
digested with HindIII and SalI and fused to the HCMVpromoter in pCMV-dhfr (Ryu et al., 1996) to yield pKC-
dhfr-HKR127.
Production of humanized KR127
The humanized heavy and light chain expression plas-
mids were cotransfected into DHFR-deficient CHO cell line
(DG44), and stably transformed cell lines were selected in a
medium containing G418 (550 Ag/ml) and subsequently
subjected to MTX selection for gene amplification, as
described previously (Ryu et al., 1996). A recombinant
CHO cell line secreting the humanized antibody was grown
in serum-free medium (CHO-S-SFMII, GIBCO/BRL), and
the culture supernatant was subjected to affinity chromatog-
raphy on Protein G-Sepharose 4B column (Pharmacia), as
described previously (Ryu et al., 1996).
ELISA analysis
Indirect ELISA
The humanized antibody was incubated with 0.1 Ag of
the GST-preS1(aa 1–56) (Kim and Hong, 1995) as a coating
antigen followed by goat anti-human IgG (Fc-specific)
peroxidase conjugate (1:1000 v/v) (Sigma). Finally, cit-
rate–PO4 buffer (pH 5.0) containing 0.04% o-phenylenedi-
amine (GIBCO/BRL) and 0.03% H2O2 was added to each
well and the plates were incubated for another 10 min. The
reaction was stopped by addition of H2SO4, and the optical
density was measured at 492 nm in an ELISA reader
(SOFTmaxPRO, Molecular Devices Corporation, USA).
Competition ELISA
A solution containing 3 ng of the purified humanized
antibody and various concentrations (1011–106 M) of the
GST-preS1 protein was incubated at 37 jC for 3 h and added
to each well that was previously coated with 0.1 Ag of the
antigen, then the indirect ELISAwas done. Apparent affinity
was determined as the reciprocal of the antigen concentration
required to inhibit 50% maximal binding in the competitive
ELISA.
Chimpanzee study
Two chimpanzees (CA0218 and CA0231), which were
born in a breeding colony in the United States (White Sands
Research Center, Alamogordo, NM) under a Food and Drug
Administration contract, were used in this study. These
animals had not been previously inoculated with any
HBV-containing materials and were seronegative for all
HBV-associated serological markers. The study chimpanzee
(CA0231) was given an intravenous injection of the hu-
manized antibody at a dose of 5 mg/kg (body weight), while
the control animal (CA0218) was given phosphate-buffered
saline (PBS). Three days later, 105 dilution of human sera
containing adr subtype of wild type HBV (kindly provided
by Dr. R.H. Purcell at NIH), whose end-point infectivity
H.J. Hong et al. / Virology 318 (2004) 134–141140titer in chimpanzees was previously determined to be 108
(Tabor et al., 1983), was inoculated intravenously into the
animals. Serum samples taken from the chimpanzees were
monitored for levels of the humanized antibody, HBsAg,
antibodies to HBcAg and HBsAg, and liver enzymes such
as alanine aminotransferase and aspartate aminotransferase.
The serum level of the humanized antibody was quantitated
by indirect ELISA using 0.2 Ag of the preS1 polypeptide
(BIODESIGN International) as a coating antigen. Serolog-
ical assays of the HBV antigens and anti-HBV antibodies
were done using commercial solid-phase radioimmunoassay
kits (Abbott Laboratories, USA).
Binding ability of humanized KR127 for different subtypes
of HBV preS1
Construction and production of preS1 variants
Alanine scanning mutagenesis or site-directed mutagen-
esis of the KR127 epitope (aa 37–45) was carried out by
recombinant PCR using pGSTpreS1-56 (Kim and Hong,
1995) as a template and mutagenic primers, and the PCR
products were subcloned into the BamHI–EcoR1 sites of
pGEX-2T (Pharmacia). Each of the resulting plasmids was
introduced into E. coli DH5a cells, and the GST-preS1
fusion proteins were expressed and purified as described
previously (Kim and Hong, 1995).
Western blot analysis
After electrophoresis, protein bands were transferred to
nitrocellulose membrane, and the membrane was incubated
with the humanized KR127 followed by goat anti-human
IgG (Fc-specific)–HRP conjugate (1:1000 v/v, Sigma).
After washing, blots were developed by adding substrate
solution containing 0.018% 4-chloro-1-naphtol (Sigma) and
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